Treatment Information

Back

Rectal Cancer treatment details. Chemotherapy.

Abramson Cancer Center , Philadelphia, PA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Philadelphia, PA
Treatments:ChemotherapyHospital:Abramson Cancer Center
Drugs:Journal:Link
Date:Oct 2008

Description:

Patients: This phase III study involved 628 patients with metastatic colorectal cancer. They ranged in age from 25 to 88. Almost all (more than 90%) had previously been treated with surgery, and about half had chemotherapy.

Treatment: Patients were treated with either the chemotherapy drugs oxaliplatin and irinotecan, or irinotecan alone.

Toxicity: Fourteen patients died from causes related to the study drug treatment. Nine were in the group treated with oxaliplatin and irinotecan (3% of patients), and five from the group treated with irinotecan alone (2% of patients). The most common grade 3 and 4 toxicities were diarrhea, granulocytopenia, vomiting, and nausea, occurring in 13-28% of patients.

Results: The median overall survival was 13.4 months for the patients treated with oxaliplatin and irinotecan, and 11.1 months for those treated with irinotecan alone.

Support: This research was supported by Sanofi-Aventis, which markets oxaliplatin as Elotaxin.

Correspondence: Dr. Daniel G. Haller



Back